Comparing Theravance Biopharma (TBPH) and Its Rivals

Theravance Biopharma (NASDAQ:TBPH) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Theravance Biopharma to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Theravance Biopharma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Theravance Biopharma Competitors	7768	13854	25724	1032	2.41

Theravance Biopharma presently has a consensus price target of $19.00, suggesting a potential upside of 11.57%. As a group, “Pharmaceuticals” companies have a potential upside of 26.18%. Given Theravance Biopharma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma has less favorable growth aspects than its competitors.

Risk and Volatility

Theravance Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Theravance Biopharma’s competitors have a beta of -3.79, suggesting that their average stock price is 479% less volatile than the S&P 500.

Earnings and Valuation

This table compares Theravance Biopharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	$105.89 million	16.86
Theravance Biopharma Competitors	$3.55 billion	$3.17 billion	547.97

Theravance Biopharma’s competitors have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.6% of Theravance Biopharma shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Theravance Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Theravance Biopharma Competitors	-2,372.59%	-220.83%	-15.99%

Summary

Theravance Biopharma competitors beat Theravance Biopharma on 8 of the 13 factors compared.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.